Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

816 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intrinsic cancer subtypes--next steps into personalized medicine.
Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R. Santos C, et al. Among authors: tabernero j. Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Cell Oncol (Dordr). 2015. PMID: 25586691 Review.
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E, Guix M, Fernández-Llamazares J, Rosell R. Font A, et al. Among authors: tabernero j. Cancer Chemother Pharmacol. 2008 Nov;62(6):1075-83. doi: 10.1007/s00280-008-0700-3. Epub 2008 Mar 12. Cancer Chemother Pharmacol. 2008. PMID: 18335219 Clinical Trial.
Colorectal Cancer OncoGuia.
Manchon Walsh P, Borràs JM, Ferro T, Espinàs JA; Colorectal Cancer OncoGuia Group. Manchon Walsh P, et al. Clin Transl Oncol. 2010 Mar;12(3):188-210. doi: 10.1007/s12094-010-0489-5. Clin Transl Oncol. 2010. PMID: 20231124 No abstract available.
A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors.
Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. Vilar E, et al. Among authors: tabernero j. Invest New Drugs. 2012 Feb;30(1):299-305. doi: 10.1007/s10637-010-9529-9. Epub 2010 Sep 7. Invest New Drugs. 2012. PMID: 20820909 Clinical Trial.
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B, Dienstmann R, Tabernero J. Markman B, et al. Among authors: tabernero j. Oncotarget. 2010 Nov;1(7):530-543. doi: 10.18632/oncotarget.188. Oncotarget. 2010. PMID: 21317449 Free PMC article. Review.
816 results